BCC patients with BCC-associated STR somatic mutations in BRAF or APC show more marked overexpression of the Notch signaling pathway (see Figure 10), and so they may be better candidates for the potential use of gamma-secretase inhibitors (GCIs) [32] or antibodies against Notch receptor or ligands [33]. Here, BRAF is linked to skin basal cell carcinoma.